Stoke Therapeutics
Biotechnology company developing antisense oligonucleotide (ASO) therapies to upregulate protein expression for haploinsufficiency diseases. Publicly traded on NASDAQ (STOK). Lead program targets Dravet syndrome.
Location
Bedford, Massachusetts, USA
Founded
2014
Investors
1
Categories
biotech, therapeutics, rna, rare-disease, public-company
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |